China’s Diabetes Race Heats Up As Novo Pins Hopes On Human Insulin EDL Inclusion; Lilly Calls For Faster Coverage
This article was originally published in PharmAsia News
Executive Summary
As Novo, Sanofi and Lilly anxiously await listings for diabetes drugs on China’s Essential Drug List, most are readying themselves with patient education efforts to boost patient numbers and compliance.
You may also be interested in...
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.